TTNP - TITAN PHARMACEUTICALS INC
IEX Last Trade
3.64
0 0%
Share volume: 100
Last Updated: Thu 26 Dec 2024 06:51:46 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$3.64
0.00
0.00%
Fundamental analysis
43%
Profitability
50%
Dept financing
20%
Liquidity
75%
Performance
34%
Performance
5 Days
6.94%
1 Month
-13.70%
3 Months
-34.13%
6 Months
-43.38%
1 Year
-35.86%
2 Year
-78.07%
Key data
Stock price
$3.64
DAY RANGE
$3.64 - $3.64
52 WEEK RANGE
$3.48 - $14.80
52 WEEK CHANGE
-$47.50
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: David E. Lazar
Region: US
Website: titanpharm.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: titanpharm.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company was incorporated in 1992 and is based in South San Francisco, California.
Recent news